The english version of the website is under development. Wherever text appears in Greek, it means it has not been translated yet.

Publications

Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.

Export 11032 results:
[ Author(Desc)] Title Type Year
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
G
Gkaliagkousi, E., Gavriilaki E., & Douma S. (2014).  The enigma of microvascular and macrovascular changes in mild essential hypertension.. J Hypertens. 32(7), 1544.
Gkaliagkousi, E., Gavriilaki E., Vasileiadis I., Nikolaidou B., Yiannaki E., Lazaridis A., et al. (2019).  Endothelial Microvesicles Circulating in Peripheral and Coronary Circulation Are Associated With Central Blood Pressure in Coronary Artery Disease.. Am J Hypertens. 32(12), 1199-1205.
Gkaliagkousi, E., Gavriilaki E., Yiannaki E., Markala D., Papadopoulos N., Triantafyllou A., et al. (2014).  Platelet activation in essential hypertension during exercise: pre- and post-treatment changes with an angiotensin II receptor blocker.. Am J Hypertens. 27(4), 571-8.
Gkaliagkousi, E., & Douma S. (2009).  The pathogenesis of arterial stiffness and its prognostic value in essential hypertension and cardiovascular diseases.. Hippokratia. 13(2), 70-5.
Gkaliagkousi, E., Passacquale G., Douma S., Zamboulis C., & Ferro A. (2010).  Platelet activation in essential hypertension: implications for antiplatelet treatment.. Am J Hypertens. 23(3), 229-36.
Gkaliagkousi, E., Gavriilaki E., Triantafyllou A., & Douma S. (2015).  Clinical Significance of Endothelial Dysfunction in Essential Hypertension.. Curr Hypertens Rep. 17(11), 85.
Gkaliagkousi, E., Douma S., Zamboulis C., & Ferro A. (2009).  Nitric oxide dysfunction in vascular endothelium and platelets: role in essential hypertension.. J Hypertens. 27(12), 2310-20.
Gkaliagkousi, E., Anyfanti P., Lazaridis A., Triantafyllou A., Vamvakis A., Koletsos N., et al. (2018).  Clinical impact of dipping and nocturnal blood pressure patterns in newly diagnosed, never-treated patients with essential hypertension.. J Am Soc Hypertens. 12(12), 850-857.
Gkaliagkousi, E., Gavriilaki E., Triantafyllou A., & Douma S. (2016).  PATHWAY-2: spironolactone for resistant hypertension.. Lancet. 387(10026), 1372.
Gkaliagkousi, E., Gavriilaki E., Triantafyllou A., Nikolaidou B., Anyfanti P., Koletsos N., et al. (2018).  Asymmetric dimethylarginine levels are associated with augmentation index across naïve untreated patients with different hypertension phenotypes.. J Clin Hypertens (Greenwich). 20(4), 680-685.
Gkaliagkousi, E., Protogerou A. D., Argyris A. A., Koletsos N., Triantafyllou A., Anyfanti P., et al. (2020).  Contribution of single office aortic systolic blood pressure measurements to the detection of masked hypertension: data from two separate cohorts.. Hypertens Res.
Gkaliagkousi, E., Gavriilaki E., Nikolaidou B., Chatzopoulou F., Anyfanti P., Triantafyllou A., et al. (2014).  Association between cardiotrophin 1 levels and central blood pressure in untreated patients with essential hypertension.. Am J Hypertens. 27(5), 651-5.
Gkaliagkousi, E., Anyfanti P., Lazaridis A., & Douma S. (2018).  Plasma renin activity to plasma aldosterone concentration ratio for the assessment of essential hypertensive patients in real-life clinical practice.. J Hypertens. 36(2), 444.
Gkaliagkousi, E., Gavriilaki E., Aslanidis S., & Douma S. (2014).  Cardiovascular risk in psoriatic arthritis: should we focus on hypertension and diabetes only?. Clin Exp Rheumatol. 32(6), 995.
Gkaliagkousi, E., Gavriilaki E., & Douma S. (2015).  Antiplatelet treatment in essential hypertension: where do we stand?. Curr Hypertens Rep. 17(4), 536.
Gkaliagkousi, E., Corrigall V., Becker S., de Winter P., Shah A., Zamboulis C., et al. (2009).  Decreased platelet nitric oxide contributes to increased circulating monocyte-platelet aggregates in hypertension.. Eur Heart J. 30(24), 3048-54.
Gkaliagkousi, E., Gavriilaki E., Triantafyllou G., Nikolaidou B., & Douma S. (2014).  The putative role of vitamin D in essential hypertension: stepping into the light?. Am J Hypertens. 27(7), 985-6.
Gkaliagkousi, E., Gavriilaki E., & Douma S. (2014).  Reply to: Seeing the forest, but not the trees: pertinent considerations for examining acute changes in pulse wave velocity in response to pharmaceutical interventions and exercise.. J Clin Hypertens (Greenwich). 16(10), 769.
Gkaliagkousi, E., Gavriilaki E., Nikolaidou B., & Douma S. (2013).  Exercise-induced platelet activation in essential hypertension: have we solved the puzzle?. J Hypertens. 31(9), 1915-6.
Gkaliagkousi, E., Anyfanti P., Triantafyllou A., Gavriilaki E., Nikolaidou B., Lazaridis A., et al. (2018).  Aldosterone as a mediator of microvascular and macrovascular damage in a population of normotensive to early-stage hypertensive individuals.. J Am Soc Hypertens. 12(1), 50-57.
Gkampeta, A., Tziola T-S., Tragiannidis A., Papageorgiou T., Spyridakis I., & Hatzipantelis E. (2019).  Primary posterior mediastinal germ cell tumor in a child.. Turk Pediatri Ars. 54(3), 185-188.
Gkampeta, A., & Pavlou E. (2012).  Emerging genetic influences in benign epilepsy with centro-temporal spikes - BECTS.. Epilepsy Res. 101(3), 197-201.
Gkampeta, A., Tziola T-S., Tragiannidis A., Papageorgiou T., Spyridakis I., & Hatzipantelis E. (2019).  Primary posterior mediastinal germ cell tumor in a child.. Turk Pediatri Ars. 54(3), 185-188.
Gkampeta, A., Fidani L., Clarimón J., Kalinderi K., Katopodi T., Zafeiriou D., et al. (2014).  Association of brain-derived neurotrophic factor (BDNF) and elongator protein complex 4 (ELP4) polymorphisms with benign epilepsy with centrotemporal spikes in a Greek population.. Epilepsy Res. 108(10), 1734-9.
Gkampeta, A., Pavlidou E., Evangeliou A., & Pavlou E. (2014).  Ketosis and EEG improvement following viral gastroenteritis in patient with West syndrome.. Brain Dev. 36(5), 411-2.

Pages

Contact

Secretariat of the School of Medicine
 

Connect

School of Medicine's presence in social networks
Follow Us or Connect with us.